Bora Pharmaceuticals Opens New Ophthalmic Manufacturing Plant in Taiwan
CDMO’s Taoyuan City plant is set to provide customers with products ranging from emulsions to gels.
Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has opened a new state-of-the-art facility in Taoyuan City, Taiwan. The 75,143 square-foot plant is expected to provide Bora’s customers with access to a range of ophthalmic manufacturing services, specializing in manufacturing Ophthalmic products such as sterile solutions, emulsions, creams, ointments, and gels.
The facility received FDA approval earlier this year and will feature two tube and two solutions lines.
“The average age of adults aged 60+ is expected to double by 2050, and, as a result of the aging population, we’ve seen demand for Ophthalmic products skyrocket in markets across the globe,”1 says Bobby Sheng, CEO of Bora Pharmaceuticals. “The opening of the new Ophthalmic site marks a significant milestone in our commitment to deliver excellence for our clients and providing services that are high in demand.”
